Scinvivo

Scinvivo is pioneering a minimally invasive imaging platform based on forward-looking Optical Coherence Tomography (OCT) to revolutionize cancer diagnostics, starting with bladder cancer. Its Lumante system, which has received FDA Breakthrough Device Designation, consists of a single-use catheter and base station, offering micrometer-level resolution to visualize subsurface tissue layers in real-time during cystoscopy. The technology addresses critical unmet needs by enabling precise local staging of tumors and reducing false positives, potentially increasing survival chances and lowering healthcare costs. While the product is not yet cleared for market (CE/FDA), the company is positioned to impact the standard of care in urological oncology.

Forward-looking Optical Coherence Tomography (OCT) miniaturized into a single-use endoscopic catheter system, providing real-time, cross-sectional, micrometer-resolution imaging of subsurface tissue anatomy. The platform includes proprietary S-Vision software for image processing and is designed for future AI integration and robotic surgery guidance.

Competition includes other advanced endoscopic imaging technologies such as confocal laser endomicroscopy (pCLE/NCLE) and high-resolution micro-ultrasound. Established medical imaging giants (e.g., Olympus, Boston Scientific) have competing or adjacent technologies. Scinvivo differentiates through its forward-looking OCT design, single-use catheter, very high resolution, and specific integration for real-time staging during standard procedures.